Screener
Travere Therapeutics, Inc. TVTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of marketable debt securities | (5,055) | — |
| Purchase of intangible assets | (22,178) | (11,784) |
| Other | — | (83) |
| Net cash provided by investing activities | 21,549 | 41,290 |
| Cash Flows From Financing Activities: | ||
| Payment of guaranteed minimum royalty | (525) | (525) |
| Proceeds from exercise of stock options | 4,729 | 4,243 |
| Net cash provided by financing activities | 4,204 | 3,718 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s investing cash flow?
- Travere Therapeutics, Inc. (TVTX) reported investing cash flow of $21.55M in Q1 2026.
- How has Travere Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Travere Therapeutics, Inc.'s investing cash flow decreased by 47.8% year-over-year, from $41.29M to $21.55M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Travere Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude